Clinical trial · Interventional
Hyperbaric Radiation Sensitization of Head and Neck Cancers
A Phase II Randomized Sham-Controlled Trial With Allocation Concealment and Blinded Patients and Assessors, Investigating Hyperbaric Oxygen as a Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx and Larynx
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There is reason to believe that hyperbaric oxygen administered immediately prior to radiotherapy will prove beneficial for this cancer type and stage. The basis for this hypothesis is a review of several decades of published work, the conclusion of a recent (2018) Cochrane Review, and results of a Phase I trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Cell Carcinoma of the Head and Neck | Head and Neck Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperbaric chamber | Device | — | UNRESOLVED |
| Hyperbaric oxygen | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group 1
- description
- Hyperbaric oxygen Hyperbaric chamber
- interventionNames
- Drug: Hyperbaric oxygen
- Device: Hyperbaric chamber
- type
- SHAM_COMPARATOR
- label
- Group 2
- description
- Sham for hyperbaric oxygen Hyperbaric chamber
- interventionNames
- Drug: Hyperbaric oxygen
- Device: Hyperbaric chamber
Primary outcomes (2)
- measure
- Progression free survival
- timeFrame
- Two years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
1. Patients with histological or microscopic proof (from the primary tumor and/or lymph nodes) of invasive squamous cell carcinoma of the oral cavity, oropharynx or larynx (World Health Organization type 1).
2. Stage III or IV disease, M0
3. Non-surgical candidate; for reasons of health or age (except biopsy)
4. Human Papillomavirus (P16) negative
5. Life expectancy of at least 6 months and a Karnofsky performance status of ≥ 70
6. Age ≥ 18 years
7. No distant metastatic disease
8. No clinically significant heart disease:
No significant ventricular arrhythmia requiring medication with antiarrhythmic. No symptomatic coronary artery disease (angina). No myocardial infarction within the last 6 months. No second or third degree heart block or bundle branch block or clinically significant conduction system abnormality.
9. Patients must sign a study-specific informed consent form
Exclusion Criteria:
1. Histology other than squamous cell carcinoma
2. Evidence of metastasis (below the clavicle or distant) by clinical or radiographic means
3. History of prior invasive malignancy, unless at least 5 years without evidence of recurrence (tumor-specific restaging)
4. Prior resection of the primary tumor or lymph node, unless un-operated N2-N3 nodal disease or primary tumor remaining, respectively.
5. Prior chemotherapy for head and neck cancer or radiotherapy to the head and neck
6. Prior treatment with Bleomycin
7. Creatinine clearance: measured or estimated Glomerular Filtration Rate \<40 ml/min.
8. Patients with simultaneous primaries
9. Pregnancy
10. Participating in a conflicting protocol
11. Pulmonary pathologies (risk of decompression-induced pulmonary barotrauma)
Current, untreated pneumothorax. Previous history of spontaneous pneumothorax. Previous history of intrathoracic surgery. History or evidence of pulmonary blebs or bullous lung disease. Clinically significant chronic obstructive pulmonary disease, associated with carbon dioxide retention, poorly controlled or associated with acute bronchospasm.
12. Where the hyperbaric physician deems the patient to have an otherwise unacceptable risk for hyperbaric chamber exposure
13. ClaustrophobiaReferences
Publications (25)
- BACKGROUNDGRAY LH. Radiobiologic basis of oxygen as a modifying factor in radiation therapy. Am J Roentgenol Radium Ther Nucl Med. 1961 May;85:803-15. No abstract available. PMID 13708070
- BACKGROUNDGRAY LH, CONGER AD, EBERT M, HORNSEY S, SCOTT OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953 Dec;26(312):638-48. doi: 10.1259/0007-1285-26-312-638. No abstract available. PMID 13106296
- BACKGROUNDGRAY LH. Oxygenation in radiotherapy. I. Radiobiological considerations. Br J Radiol. 1957 Aug;30(356):403-6. doi: 10.1259/0007-1285-30-356-403. No abstract available. PMID 13446401
- BACKGROUNDCHURCHILL-DAVIDSON I, SANGER C, THOMLINSON RH. High-pressure oxygen and radiotherapy. Lancet. 1955 May 28;268(6874):1091-5. doi: 10.1016/s0140-6736(55)90589-4. No abstract available. PMID 14382503
- BACKGROUNDCHURCHILL-DAVIDSON I, SANGER C, THOMLINSON RH. Oxygenation in radiotherapy. II. Clinical application. Br J Radiol. 1957 Aug;30(356):406-22. doi: 10.1259/0007-1285-30-356-406. No abstract available. PMID 13446402
- BACKGROUNDEMERY EW, LUCAS BG, WILLIAMS KG. Technique of irradiation of conscious patients under increased oxygen pressure. Lancet. 1960 Jan 30;1(7118):248-50. doi: 10.1016/s0140-6736(60)90170-7. No abstract available. PMID 13820164
- BACKGROUNDSANGER C. High pressure oxygen and radiation therapy. Am J Roentgenol Radium Ther Nucl Med. 1959 Mar;81(3):498-503. No abstract available. PMID 13627317
- BACKGROUNDATKINS HL, SEAMAN WB, JACOX HW, MATTEO RS. EXPERIENCE WITH HYPERBARIC OXYGENATION IN CLINICAL RADIOTHERAPY. Am J Roentgenol Radium Ther Nucl Med. 1965 Mar;93:651-63. No abstract available.